Evolving pharmacological approaches in gastroesophageal reflux disease

  title={Evolving pharmacological approaches in gastroesophageal reflux disease},
  author={E. Altan and K. Blondeau and A. Pauwels and R. Farr{\'e} and J. Tack},
  journal={Expert Opinion on Emerging Drugs},
  pages={347 - 359}
  • E. Altan, K. Blondeau, +2 authors J. Tack
  • Published 2012
  • Medicine
  • Expert Opinion on Emerging Drugs
  • Introduction: Proton pump inhibitors (PPIs) have considerably improved quality of life in patients with gastroesophageal reflux disease (GERD). However, many patients remain symptomatic despite standard PPI therapy. Areas covered: This review focuses on evolving therapeutic strategies related to the pathophysiological processes of GERD and insufficient response to PPIs. Several clinical trials evaluated new PPI formulations and newer types of acid-suppressive drugs. These studies have evaluated… CONTINUE READING
    Research advances in esophageal diseases: bench to bedside
    • 15
    • Open Access
    Management of reflux-related symptoms.
    • 6
    Supraesophageal reflux disease: a review of the literature.
    • 4
    • Highly Influenced


    Publications referenced by this paper.
    Epidemiology of gastro-oesophageal reflux disease: a systematic review
    • 1,576
    • Open Access
    Management of heartburn not responding to proton pump inhibitors
    • 270
    The proton-pump inhibitors: similarities and differences.
    • 211
    The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis.
    • 227